Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematologic Neoplasms | 7 | 2023 | 329 | 2.980 |
Why?
|
| Prostate-Specific Antigen | 5 | 2016 | 352 | 1.750 |
Why?
|
| Genetic Predisposition to Disease | 14 | 2023 | 2270 | 1.550 |
Why?
|
| Early Detection of Cancer | 5 | 2016 | 392 | 1.500 |
Why?
|
| Germ-Line Mutation | 9 | 2023 | 329 | 1.400 |
Why?
|
| Mesothelioma | 3 | 2024 | 311 | 1.110 |
Why?
|
| Life Expectancy | 3 | 2015 | 86 | 1.080 |
Why?
|
| Neoplasms | 5 | 2023 | 2897 | 0.970 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2023 | 763 | 0.940 |
Why?
|
| Myeloproliferative Disorders | 1 | 2023 | 110 | 0.800 |
Why?
|
| Prostatic Neoplasms | 5 | 2016 | 1720 | 0.740 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 62 | 0.730 |
Why?
|
| Leukemia | 2 | 2023 | 320 | 0.690 |
Why?
|
| Mass Screening | 4 | 2016 | 617 | 0.640 |
Why?
|
| Precision Medicine | 2 | 2021 | 395 | 0.630 |
Why?
|
| Myelodysplastic Syndromes | 4 | 2022 | 346 | 0.540 |
Why?
|
| Lymphoma | 1 | 2016 | 262 | 0.510 |
Why?
|
| Testosterone | 1 | 2016 | 271 | 0.510 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2016 | 111 | 0.510 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2023 | 456 | 0.500 |
Why?
|
| Humans | 34 | 2024 | 86601 | 0.440 |
Why?
|
| Radiosurgery | 1 | 2016 | 272 | 0.440 |
Why?
|
| Germ Cells | 4 | 2023 | 126 | 0.440 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 581 | 0.440 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2024 | 173 | 0.430 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 1056 | 0.410 |
Why?
|
| Decision Making | 1 | 2014 | 642 | 0.320 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 3 | 2023 | 52 | 0.310 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 1464 | 0.290 |
Why?
|
| Age Factors | 4 | 2018 | 1849 | 0.280 |
Why?
|
| Selection Bias | 2 | 2016 | 37 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-ets | 2 | 2022 | 25 | 0.260 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2024 | 24 | 0.240 |
Why?
|
| Male | 10 | 2023 | 40956 | 0.230 |
Why?
|
| DNA Helicases | 1 | 2023 | 79 | 0.220 |
Why?
|
| Mutation | 4 | 2023 | 3967 | 0.220 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2023 | 127 | 0.220 |
Why?
|
| Genomics | 3 | 2023 | 720 | 0.220 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2023 | 58 | 0.220 |
Why?
|
| Syndrome | 1 | 2023 | 446 | 0.210 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 2887 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2024 | 589 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2016 | 864 | 0.210 |
Why?
|
| Blood Platelet Disorders | 1 | 2021 | 9 | 0.210 |
Why?
|
| Aged | 6 | 2018 | 18402 | 0.200 |
Why?
|
| Peritoneal Neoplasms | 1 | 2023 | 176 | 0.200 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2023 | 302 | 0.200 |
Why?
|
| Megakaryocytes | 1 | 2021 | 36 | 0.200 |
Why?
|
| Venous Thromboembolism | 1 | 2024 | 153 | 0.200 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 567 | 0.200 |
Why?
|
| Pulmonary Embolism | 1 | 2024 | 221 | 0.200 |
Why?
|
| Neutropenia | 1 | 2021 | 215 | 0.190 |
Why?
|
| Appendicitis | 1 | 2021 | 62 | 0.190 |
Why?
|
| Genetic Testing | 3 | 2022 | 535 | 0.190 |
Why?
|
| Hematopoiesis | 1 | 2021 | 163 | 0.190 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 183 | 0.180 |
Why?
|
| United States | 5 | 2024 | 6665 | 0.180 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2021 | 104 | 0.180 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 375 | 0.180 |
Why?
|
| Middle Aged | 5 | 2023 | 25017 | 0.170 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 252 | 0.170 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2018 | 5 | 0.160 |
Why?
|
| Risk | 2 | 2021 | 674 | 0.160 |
Why?
|
| Repressor Proteins | 1 | 2021 | 403 | 0.160 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2018 | 59 | 0.160 |
Why?
|
| Health Surveys | 2 | 2015 | 239 | 0.150 |
Why?
|
| Orchiectomy | 1 | 2016 | 68 | 0.140 |
Why?
|
| Gene Frequency | 1 | 2018 | 677 | 0.140 |
Why?
|
| Prognosis | 3 | 2021 | 3674 | 0.140 |
Why?
|
| Standard of Care | 1 | 2016 | 78 | 0.130 |
Why?
|
| Androgen Antagonists | 1 | 2016 | 144 | 0.130 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2015 | 155 | 0.130 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 6501 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 853 | 0.120 |
Why?
|
| Adult | 6 | 2024 | 25640 | 0.120 |
Why?
|
| Interviews as Topic | 1 | 2015 | 319 | 0.120 |
Why?
|
| Mental Recall | 1 | 2015 | 159 | 0.120 |
Why?
|
| Genome, Human | 1 | 2018 | 756 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2015 | 223 | 0.120 |
Why?
|
| Female | 4 | 2023 | 44507 | 0.110 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 204 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1384 | 0.110 |
Why?
|
| Survival Rate | 1 | 2016 | 1860 | 0.100 |
Why?
|
| Biopsy | 1 | 2015 | 1161 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2018 | 1351 | 0.100 |
Why?
|
| Research Design | 1 | 2015 | 594 | 0.100 |
Why?
|
| Health Status | 1 | 2014 | 360 | 0.100 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 1621 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2016 | 534 | 0.100 |
Why?
|
| Young Adult | 2 | 2024 | 5974 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 2261 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2014 | 770 | 0.090 |
Why?
|
| Comorbidity | 1 | 2014 | 943 | 0.090 |
Why?
|
| Logistic Models | 1 | 2014 | 1185 | 0.090 |
Why?
|
| Testicular Neoplasms | 1 | 2011 | 105 | 0.090 |
Why?
|
| Smoking | 1 | 2014 | 609 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2011 | 219 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1673 | 0.090 |
Why?
|
| Risk Factors | 2 | 2024 | 5416 | 0.090 |
Why?
|
| Clathrin | 1 | 2007 | 29 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2024 | 8475 | 0.080 |
Why?
|
| Protein Structure, Quaternary | 1 | 2007 | 99 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 1034 | 0.060 |
Why?
|
| Blast Crisis | 1 | 2024 | 33 | 0.060 |
Why?
|
| GATA2 Transcription Factor | 1 | 2023 | 14 | 0.060 |
Why?
|
| Philadelphia Chromosome | 1 | 2024 | 38 | 0.060 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2024 | 107 | 0.060 |
Why?
|
| World Health Organization | 1 | 2023 | 103 | 0.060 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2023 | 62 | 0.060 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 78 | 0.060 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2023 | 72 | 0.060 |
Why?
|
| Cytogenetics | 1 | 2021 | 27 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2023 | 195 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2022 | 179 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2021 | 109 | 0.050 |
Why?
|
| Genetic Counseling | 1 | 2021 | 100 | 0.050 |
Why?
|
| Emergencies | 1 | 2021 | 113 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2021 | 265 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2024 | 408 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 140 | 0.050 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 71 | 0.050 |
Why?
|
| Chromosome Aberrations | 1 | 2021 | 387 | 0.050 |
Why?
|
| Registries | 1 | 2021 | 702 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 294 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2021 | 2818 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 327 | 0.030 |
Why?
|
| Computational Biology | 1 | 2018 | 528 | 0.030 |
Why?
|
| Alleles | 1 | 2018 | 1127 | 0.030 |
Why?
|
| Phenotype | 1 | 2021 | 2377 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 878 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2023 | 4210 | 0.030 |
Why?
|
| Models, Biological | 1 | 2021 | 1749 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2024 | 2207 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2012 | 90 | 0.030 |
Why?
|
| Americas | 1 | 2011 | 19 | 0.030 |
Why?
|
| Asia | 1 | 2011 | 94 | 0.020 |
Why?
|
| Africa | 1 | 2011 | 98 | 0.020 |
Why?
|
| Australia | 1 | 2011 | 99 | 0.020 |
Why?
|
| Adolescent | 1 | 2024 | 8979 | 0.020 |
Why?
|
| Europe | 1 | 2011 | 309 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2011 | 197 | 0.020 |
Why?
|
| Sarcosine | 1 | 2007 | 2 | 0.020 |
Why?
|
| Detergents | 1 | 2007 | 34 | 0.020 |
Why?
|
| Cattle | 1 | 2007 | 376 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 1576 | 0.020 |
Why?
|
| Child | 1 | 2018 | 6926 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 339 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2007 | 736 | 0.020 |
Why?
|
| Time Factors | 1 | 2011 | 5209 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 26581 | 0.000 |
Why?
|